Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classifica tra le azioni #4551
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$27.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
-1.41%
Variazione (1 anno)
202.34%
Paese
US
Scambia Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Tango Therapeutics, Inc. (TNGX)
L’azione Tango Therapeutics, Inc. (simbolo: TNGX) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Oct 21, 2026.
Una quota di TNGX acquistata prima di Oct 21, 2026 equivale oggi a 0 quote di TNGX.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL